Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Blood

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Blood|October 30, 2007
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patientsUlrike Bacher, Claudia Haferlach, Wolfgang Kern, et al.
Blood|November 18, 2021
Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data setChristian Matek, Sebastian Krappe, Christian Münzenmayer, et al.
Blood|July 15, 2006
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expressionFrank Dicker, Susanne Schnittger, Torsten Haferlach, et al.
Blood|January 26, 2006
Implications of NRAS mutations in AML: a study of 2502 patientsUlrike Bacher, Torsten Haferlach, Claudia Schoch, et al.
Blood|May 9, 2007
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemiaFrank Dicker, Claudia Haferlach, Wolfgang Kern, et al.
Blood|June 14, 2003
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML casesClaudia Schoch, Susanne Schnittger, Mirjam Klaus, et al.
Blood|September 1, 2010
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 statusSusanne Schnittger, Claudia Haferlach, Madlen Ulke, et al.
Blood|July 31, 2004
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemiaWolfgang Kern, Daniela Voskova, Claudia Schoch, et al.
Blood|October 18, 2002
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemiaKarsten Spiekermann, Ksenia Bagrintseva, Claudia Schoch, et al.
Blood|July 5, 2003
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcriptsSusanne Schnittger, Martin Weisser, Claudia Schoch, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Blood|October 30, 2007
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patientsUlrike Bacher, Claudia Haferlach, Wolfgang Kern, et al.
Blood|November 18, 2021
Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data setChristian Matek, Sebastian Krappe, Christian Münzenmayer, et al.
Blood|July 15, 2006
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expressionFrank Dicker, Susanne Schnittger, Torsten Haferlach, et al.
Blood|January 26, 2006
Implications of NRAS mutations in AML: a study of 2502 patientsUlrike Bacher, Torsten Haferlach, Claudia Schoch, et al.
Blood|May 9, 2007
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemiaFrank Dicker, Claudia Haferlach, Wolfgang Kern, et al.
Blood|June 14, 2003
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML casesClaudia Schoch, Susanne Schnittger, Mirjam Klaus, et al.
Blood|September 1, 2010
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 statusSusanne Schnittger, Claudia Haferlach, Madlen Ulke, et al.
Blood|July 31, 2004
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemiaWolfgang Kern, Daniela Voskova, Claudia Schoch, et al.
Blood|October 18, 2002
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemiaKarsten Spiekermann, Ksenia Bagrintseva, Claudia Schoch, et al.
Blood|July 5, 2003
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcriptsSusanne Schnittger, Martin Weisser, Claudia Schoch, et al.
Pageof 8